Inabata Inabata

X
[{"orgOrder":0,"company":"Octantbio","sponsor":"Catalio Capital Management","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Octant Raises $80 Million Series B Round to Support Expansion of Next-Generation Drug Discovery Platform, Announces Collaboration with Bristol Myers Squibb and Key Appointments","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery"}]

Find Clinical Drug Pipeline Developments & Deals by Octantbio

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Proceeds from Series B will be used to expand Octant’s platform capabilities and pipeline, advance its proprietary drug discovery technology, and generate extensive datasets that map the relationships between drug candidates, genetics, and biochemical mechanism of human cells.

            Lead Product(s): Chaperon Therapy

            Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Catalio Capital Management

            Deal Size: $80.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing April 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY